To print: Select File and then Print from your browser's menu

Title: Tadalafil Most Effective Treatment for Severe Erectile Dysfunction, Preferred by Patients: Presented at ESSM-ISSM

"Tadalafil Most Effective Treatment for Severe Erectile Dysfunction, Preferred by Patients: Presented at ESSM-ISSM"

By Chris Berrie BRUSSELS, Belgium -- December 9, 2008 -- Tadalafil is slightly more effective than sildenafil and vardenafil in treating men with severe erectile dysfunction (ED), and more ED patients preferred tadalafil for erection quality, according to a prospective, randomised study presented at the Joint Congress of the European and International Societies for Sexual Medicine (ESSM-ISSM). The aim of this open-label, fixed-dose, crossover study was to determine the effectiveness and side effects of, the differences between, and the patient preference for the 3 phosphodiesterase-5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil. Jose Maria Cuadrado, MD, Hospital Universitario de Bellvitge, Barcelona, Spain, indicated that patient inclusion was specified as severe erectile dysfunction with an evolution of greater than 6 months and an International Index of Erectile Function (IIEF) score of 10 or less. "Sildenafil 100 mg, vardenafil 20 mg, and tadalafil 20 mg were taken at least 4 times [by each patient] over a period of 30 to 45 days, with a washout period of 7 days," Dr. Cuadrado described, speaking here at a poster presentation on December 8. The baseline characteristics of the 108 patients who completed the study were as follows: average age 55.9 years; average time of evolving ED 28.4 months; associated comorbidities 94%; average IIEF score 8.52. As post-treatment comparisons were made with baseline values, the mean IIEF scores showed tadalafil (21.74) to be slightly, but significantly, more effective than both sildenafil (20.56; [P = .003) and vardenafil (20.64; P = .001), which were not significantly different from each other.

Similarly, the patient (n = 108) and partner (n = 75) Erectile Dysfunction Inventory for Treatment Satisfaction scores generally demonstrated small but significant benefits for tadalafil (28.65 and 11.47, respectively) over both sildenafil (27.07, P = .027; 10.84, P = .158) and vardenafil (27.29, P = .027; 10.41, P = .013). Again, no differences were seen between sildenafil and vardenafil.

For the Sexual Encounter Profile (SEP), Dr. Cuadrado noted, "Questions SEP4 and SEP5 were significantly in favour of tadalafil over sildenafil and vardenafil [38.09 vs 31.20 vs 32.10, P = .025; 41.43 vs 33.42 vs 35.85, P = .025; respectively]".

Patient preference according to erection quality was also seen to favour tadalafil (39.8%) over both sildenafil (18.5%) and vardenafil (17.6%), although 24.1% of patients also expressed no specific preference.

[Presentation title: Effectiveness and Preference Study in Patients With Severe Erectile Dysfunction, After Taking the Three Phosphodiesterase-5 Inhibitors. Abstract MP-028]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.